Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

  • Conferences
    • AACR19
    • AACR18
    • AACR17
    • AACR16
    • AACR15
    • AACR14
    • AACR IO
    • AAI ASGCT
    • ASCO GI
    • ASCO GU
    • ASCO-SITC
    • ASCO19
    • ASCO18
    • ASCO17
    • ASCO16
    • ASCO15
    • ASCO14
    • ASH18
    • ASH17
    • ASH16
    • ASH15
    • AUA
    • BMT
    • CIML40
    • CIMT
    • EACR
    • EAU
    • ECCO
    • ESMO19
    • ESMO18
    • ESMO17
    • ESMO16
    • ESMO14
    • JPM
    • SABCS
    • SITC 2019
    • SITC 2018
    • SITC 2017
    • SITC 2016
    • SITC 2015
    • SITC 2014
    • Targets19
  • Targets
    • Bispecifics
    • Cytokines
    • MYC
    • Neoantigens
    • RAS
    • STING
  • About
  • Contact
  • Pricing
  • ASH19
  • Premium Content
  • Immuno-Oncology
  • Cell Therapy
  • Interviews
  • Podcast
  • Login

  • Is pembrolizumab superior to atezolizumab in neoadjuvant TNBC?

    Read more

  • Highlights and lowlights in HER2+ metastatic breast cancer at SABCS19

    Read more

  • In Plain Sight

    Read more

  • Friday Scientific Workshops are the Perfect Warm-Up act to ASH19

    Read more

  • 10 early phase ASH19 abstracts with a difference

    Read more

  • 9 up and coming non-T cell based immunotherapy approaches

    Read more

  • ASH19 10 innovative approaches in Hematologic Malignancies

    Read more

  • New developments in targeting the B cell receptor pathway

    Read more
E

Is pembrolizumab superior to atezolizumab in neoadjuvant TNBC?

A look at the KEYNOTE-522 and neoTRIP clinical trials in neoadjuvant TNBC

View post
E

Highlights and lowlights in HER2+ metastatic breast cancer at SABCS19

A look at tucatinib, margetuximab and trastuzumab deruxtecan in HER2+ advanced MBC

View post
E

In Plain Sight

A look at some of the highly ranked clinical data presented over the weekend in Orlando

View post

Terms of Use & Privacy Policy
Copyright © 2010-19 Biotech Strategy Blog

error: Content is protected !!